Cantor Fitzgerald Reiterates “$222.00” Price Target for Shire (SHPG)
A number of other research analysts also recently issued reports on SHPG. Barclays downgraded Shire from an overweight rating to an equal weight rating in a research note on Friday, August 11th. Jefferies Group restated a hold rating and set a $206.00 price target (down previously from $216.00) on shares of Shire in a research note on Wednesday, August 9th. Royal Bank Of Canada restated a buy rating and set a $213.00 price target on shares of Shire in a research note on Monday, October 2nd. FBR & Co restated a buy rating and set a $201.00 price target on shares of Shire in a research note on Monday, October 30th. Finally, Liberum Capital upgraded Shire from a hold rating to a buy rating in a research note on Tuesday, November 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $212.18.
Shire (NASDAQ SHPG) traded up $4.64 on Tuesday, hitting $148.00. The stock had a trading volume of 895,244 shares, compared to its average volume of 1,057,178. Shire has a fifty-two week low of $137.17 and a fifty-two week high of $192.15. The stock has a market cap of $43,069.21, a P/E ratio of 9.86, a P/E/G ratio of 0.80 and a beta of 1.59. The company has a current ratio of 0.98, a quick ratio of 0.52 and a debt-to-equity ratio of 0.55.
Shire (NASDAQ:SHPG) last released its quarterly earnings results on Friday, October 27th. The biopharmaceutical company reported $3.81 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.64 by $0.17. The firm had revenue of $3.70 billion for the quarter. Shire had a return on equity of 14.41% and a net margin of 10.95%. The company’s quarterly revenue was up 7.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.17 EPS. analysts forecast that Shire will post 15 EPS for the current year.
A number of institutional investors have recently bought and sold shares of SHPG. YorkBridge Wealth Partners LLC lifted its holdings in shares of Shire by 81.7% in the 2nd quarter. YorkBridge Wealth Partners LLC now owns 705 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 317 shares during the period. BB&T Investment Services Inc. lifted its holdings in shares of Shire by 1,672.3% in the 3rd quarter. BB&T Investment Services Inc. now owns 833 shares of the biopharmaceutical company’s stock valued at $127,000 after buying an additional 786 shares during the period. Steward Partners Investment Advisory LLC acquired a new stake in shares of Shire in the 3rd quarter valued at approximately $159,000. Pacer Advisors Inc. acquired a new stake in shares of Shire in the 2nd quarter valued at approximately $171,000. Finally, Stephens Inc. AR lifted its holdings in shares of Shire by 22.2% in the 2nd quarter. Stephens Inc. AR now owns 1,256 shares of the biopharmaceutical company’s stock valued at $208,000 after buying an additional 228 shares during the period. 20.28% of the stock is owned by institutional investors.
WARNING: This article was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/12/09/cantor-fitzgerald-reiterates-222-00-price-target-for-shire-shpg.html.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.